Keyword: Department of Health and Human Services (HHS)
Measures in Trump's 2020 budget aim to incentivize lower list prices, promote competition and more.
UnitedHealthcare is making demands about pharma's new strategy to lower prices, an analyst wrote.
Top PBM Express Scripts said that its efforts saved clients $45 billion in 2018, and its clients' drug costs grew just 0.4% last year.
Johnson & Johnson is the first pharma to announce it will put drug list prices directly in TV ads, self-regulating ahead of a proposed regulation.
Sweep out drug rebates for patient discounts instead? Supply chain players hate the idea, but Big Pharma CEOs are all over it.
As the Trump administration weighs ending rebates to PBMs, their trade group has debuted ads asserting the cost-cutting value of the industry middlemen.
HHS chief Alex Azar said Congress should push the rebating proposal to commercial insurance. But one analyst thinks that statement's all about subtext.
The Trump administration aims to nix pharma's secret rebates on Medicare drugs, shaking up the industry's pricing and discounting strategies.
Between President Trump on Twitter and critics in Congress, pharma and its pricing faced daily fire last year. But the industry's top lobbyists shot back.
The Democrats' new drug pricing bills are "flawed"—and likely to fail—unless Trump crosses the aisle. And as one analyst sees it, he just might.